Cancer Immunotherapy Trials Underutilize Immune Response Monitoring

Publisher： John Wiley & Sons Inc

E-ISSN： 1549-490x|23|1|116-117

ISSN： 1083-7159

Source： The Oncologist, Vol.23, Iss.1, 2018-01, pp. : 116-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer

By  

Current Cancer Therapy Reviews, Vol. 8, Iss. 4, 2012-11 ,pp. : 254-263

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical trials of immunotherapy for advanced prostate cancer

By Kuratsukuri K.   Nishisaka N.   Jones R.F.   Wang C.Y.   Haas G.P.  

Urologic Oncology: Seminars and Original Investigations, Vol. 5, Iss. 6, 2000-11 ,pp. : 265-273

Elsevier

Access to resources Recommend Favorite

Effective immunotherapy against cancer: A question of overcoming immune suppression and immune escape?

By Malmberg Karl-Johan  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 10, 2004-10 ,pp. : 879-892

Springer Publishing Company

Access to resources Recommend Favorite

Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 8, Iss. 1, 2008-01 ,pp. : 86-91

Bentham Science Publishers

Access to resources Recommend Favorite

Improving cancer immunotherapy by targeting tumor-induced immune suppression

By Stewart Trina  

Cancer and Metastasis Reviews, Vol. 30, Iss. 1, 2011-03 ,pp. : 125-140

Springer Publishing Company

Access to resources Recommend Favorite